

Åystein Rekdal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/269551/publications.pdf>

Version: 2024-02-01

34
papers

2,055
citations

279798

23
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

2302
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
2	Antimicrobial activity of short arginine- and tryptophan-rich peptides. Journal of Peptide Science, 2002, 8, 431-437.	1.4	131
3	Antibacterial activity of 15-residue lactoferricin derivatives. Chemical Biology and Drug Design, 2000, 56, 265-274.	1.1	125
4	Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO Journal, 2018, 37, .	7.8	81
5	Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. Journal of Medicinal Chemistry, 2016, 59, 2918-2927.	6.4	77
6	Construction and synthesis of lactoferricin derivatives with enhanced antibacterial activity. Journal of Peptide Science, 1999, 5, 32-45.	1.4	71
7	Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunology, Immunotherapy, 2014, 63, 601-613.	4.2	70
8	A novel biological effect of platelet factor 4 (PF4): enhancement of LPS-induced tissue factor activity in monocytes. Journal of Leukocyte Biology, 1995, 58, 575-581.	3.3	69
9	The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. Journal of Peptide Science, 2004, 10, 37-46.	1.4	65
10	LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. Future Medicinal Chemistry, 2017, 9, 1339-1344.	2.3	60
11	The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget, 2015, 6, 34910-34923.	1.8	52
12	Effect of marine oils supplementation on coagulation and cellular activation in whole blood. Lipids, 1995, 30, 1111-1118.	1.7	50
13	LTX-315 (Oncoporeâ„„). Oncoimmunology, 2014, 3, e29181.	4.6	46
14	Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. Journal of Peptide Science, 2003, 9, 300-311.	1.4	44
15	Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilicN-terminal modifications. Journal of Peptide Science, 2003, 9, 510-517.	1.4	43
16	The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget, 2015, 6, 26599-26614.	1.8	42
17	Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. Breast Cancer Research, 2019, 21, 9.	5.0	40
18	The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. Journal of Peptide Science, 2002, 8, 36-43.	1.4	38

#	ARTICLE	IF	CITATIONS
19	Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. <i>Oncolmmunology</i> , 2017, 6, e1338236.	4.6	36
20	Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. <i>Trends in Cancer</i> , 2021, 7, 557-572.	7.4	33
21	The oncolytic peptide LTX-315 triggers necrotic cell death. <i>Cell Cycle</i> , 2015, 14, 3506-3512.	2.6	30
22	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. <i>Oncolmmunology</i> , 2021, 10, 1962592.	4.6	30
23	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2755-2763.	7.0	29
24	Tumor lysis with LTX-401 creates anticancer immunity. <i>Oncolmmunology</i> , 2019, 8, e1594555.	4.6	26
25	The oncolytic compound LTX-401 targets the Golgi apparatus. <i>Cell Death and Differentiation</i> , 2016, 23, 2031-2041.	11.2	25
26	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. <i>Cell Death and Disease</i> , 2018, 9, 1086.	6.3	20
27	Th1 clones that suppress IgG2ab specifically recognize an allopeptide determinant comprising residues 435-451 of Î²2ab. <i>European Journal of Immunology</i> , 1993, 23, 2655-2660.	2.9	19
28	LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects. <i>Cell Stress</i> , 2019, 3, 348-360.	3.2	19
29	Recruitment of LC3 to damaged Golgi apparatus. <i>Cell Death and Differentiation</i> , 2019, 26, 1467-1484.	11.2	18
30	The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 139-148.	4.4	17
31	The Cytolytic Amphipathic Î²(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma. <i>PLoS ONE</i> , 2016, 11, e0148980.	2.5	14
32	Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 177.	0.8	12
33	A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties. <i>Experimental Cell Research</i> , 2017, 352, 218-224.	2.6	8
34	Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6731.	3.3	5